Developer docs
API playgroundTry for free, no card

Search company profiles

Kymera Therapeutics

Full company profile

uuid0000j9v

Namestring
Kymera Therapeutics
Legal namestring
Kymera Therapeutics, Inc.
Websiteurl
kymeratx.com
Company typeenum
Public
Founded yearint
2016
Descriptiontext

Kymera Therapeutics is a clinical-stage biopharmaceutical company founded in 2016 that pioneers targeted protein degradation (TPD), a modality which uses heterobifunctional small molecule degraders and molecular glues to redirect the cell's ubiquitin-proteasome system to eliminate disease-causing proteins, including those historically considered undruggable. The company's clinical pipeline is anchored by KT-621, a first-in-class once-daily oral STAT6 degrader in Phase 2b development for moderate-to-severe atopic dermatitis (BROADEN2) and eosinophilic asthma (BREADTH), which received FDA Fast Track designation for both indications based on Phase 1b data showing 98% STAT6 degradation in blood and 94% in skin, with 63% EASI reduction comparable to dupilumab. Additional clinical programs include KT-579 (first-in-class oral IRF5 degrader in Phase 1 for lupus), KT-485 (second-generation IRAK4 degrader in Phase 1, partnered with Sanofi), and KT-200 (first-in-class oral CDK2 molecular glue partnered with Gilead). The pipeline is supported by the proprietary Pegasus discovery platform, which integrates DNA-encoded libraries, fragment-based screening, AI/ML-enabled hit optimization, X-ray crystallography, cryo-EM, and access to over 600 unique E3 ligases to match target proteins with disease-selective ligases.

The Pegasus platform and degrader programs are protected by 500+ issued or pending patents, and the company is led by founder/CEO Nello Mainolfi (former Novartis) with a 250+ employee team headquartered in Watertown, Massachusetts, traded on NASDAQ as KYMR since a 2021 IPO. Kymera generates revenue primarily through collaboration agreements with major pharmaceutical partners — Sanofi (IRAK4 program, up to $975M in milestones plus 50/50 US profit split and double-digit tiered royalties ex-US) and Gilead Sciences (CDK2 program, up to $750M plus royalties, option exercised April 2026) — alongside equity financings; the company has no commercial product revenue, with FY2025 collaboration revenue of $39.2M and Q1 2026 collaboration revenue of $34.36M driven by a Gilead milestone. Management has stated intent to evolve from clinical-stage developer toward a fully integrated biopharma that discovers, develops, and commercializes its own medicines, supported by approximately $1.6B in cash providing runway into 2029 and a market capitalization of approximately $8.2B as of June 2026.

Short descriptiontext

Kymera Therapeutics is a clinical-stage biopharmaceutical company pioneering targeted protein degradation to develop first-in-class oral small molecule degraders for Type 2 inflammatory, autoimmune, and oncology diseases, serving patients and large pharma partners (Sanofi, Gilead) through wholly owned and partnered programs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersWatertown, United States
HQ citystring
Watertown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
targeted protein degradation, protein degrader medicines, small molecule degraders, immunology therapeutics, oncology drug development
Industry1 code
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals (Targeted Protein Degradation Therapeutics)
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Collaboration/Partnership Revenue
TypeLicensing Royalties
Description

Kymera generates revenue through strategic collaborations with major pharmaceutical companies. The company has collaboration agreements with Sanofi (IRAK4 program) and Gilead Sciences (CDK2 program), receiving milestone payments and potentially royalties on net sales. As a clinical-stage company with no commercial products, revenue is derived from upfront payments, development and regulatory milestones, and potentially sales milestones and royalties.

tradingview.com
2Public Offerings / Equity Financing
TypeLicensing Royalties
Description

The company has raised significant capital through public equity offerings. In 2025, the company raised approximately $980.7 million through follow-on public offerings, ending 2025 with $1,619.4 million in cash, cash equivalents, and marketable securities.

tradingview.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Kymera Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops oral small molecule medicines using targeted protein degradation (TPD), a modality that hijacks the cell's natural protein disposal machinery to eliminate disease-causing proteins. Its pipeline includes first-in-class oral degrader candidates (KT-621, KT-579, KT-485, KT-200, KT-474) for immunology and oncology indications, enabled by the proprietary Pegasus drug discovery platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • KT-621 achieved 98% STAT6 degradation in blood and 94% in skin in Phase 1b atopic dermatitis patients
+7 more records
Product overview1 text field

Kymera Therapeutics is a clinical-stage biopharmaceutical company pioneering targeted protein degradation (TPD) to develop a pipeline of first-in-class oral small molecule degrader medicines. The company's pipeline includes multiple clinical-stage programs: KT-621 (STAT6 degrader) in Phase 2b for atopic dermatitis and asthma; KT-579 (IRF5 degrader) in Phase 1 for lupus; KT-485 (IRAK4 degrader) in Phase 1 partnered with Sanofi; and KT-200 (CDK2 molecular glue degrader) partnered with Gilead. The proprietary Pegasus platform enables the discovery and development of heterobifunctional degraders that engage E3 ligases to selectively eliminate disease-causing proteins, addressing targets previously considered undruggable.

Product and service6 records
1KT-621 (STAT6 Degrader)
CategoryClinical-Stage Immunology Therapeutic
Description

First-in-class, once-daily oral STAT6 degrader for Type 2 inflammatory diseases including moderate-to-severe atopic dermatitis, eosinophilic asthma, COPD, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, prurigo nodularis, and bullous pemphigoid. Demonstrated 98% STAT6 degradation in blood and 94% in skin in Phase 1b, with clinical efficacy comparable to dupilumab.

2KT-579 (IRF5 Degrader)
CategoryClinical-Stage Autoimmune Therapeutic
Description

First-in-class oral IRF5 degrader targeting the historically undrugged transcription factor IRF5 for lupus, Sjögren's syndrome, rheumatoid arthritis, inflammatory bowel disease, systemic sclerosis, and dermatomyositis.

3KT-485 (IRAK4 Degrader / SAR447971)
CategoryClinical-Stage Immunology Therapeutic (Sanofi-Partnered)
Description

Second-generation, first-in-class, selective, potent, oral IRAK4 degrader partnered with Sanofi for immune-inflammatory diseases including hidradenitis suppurativa, atopic dermatitis, psoriasis, IBD, asthma, COPD, RA, and SLE.

4KT-200 (CDK2 Molecular Glue Degrader)
CategoryClinical-Stage Oncology Therapeutic (Gilead-Partnered)
Description

First-in-class oral CDK2 molecular glue degrader partnered with Gilead Sciences for breast cancer and other solid tumors. CDK2 is a master regulator of the cell cycle with strong genetic and clinical validation; selectively degrades CDK2 while sparing closely related kinases like CDK1.

5KT-474 (First-generation IRAK4 Degrader)
CategoryClinical-Stage Immunology Therapeutic (Sanofi-Partnered)
Description

First-generation oral IRAK4 degrader; the first heterobifunctional small molecule protein degrader outside of oncology to enter clinical development. Completed Phase 1 studies and provided proof-of-concept for the company's degrader modality.

6Pegasus Discovery Platform
CategoryDrug Discovery Platform / Technology
Description

Proprietary targeted protein degradation drug discovery platform combining DNA encoded libraries, fragment and X-ray based screenings, machine learning and AI for hit-validation and optimization, structure-based drug design, and global quantitative proteomics to match target proteins with optimal E3 ligases from a library of over 600 unique options.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-06-25
Description

Kymera and Gilead Sciences entered an exclusive option and license agreement for a novel molecular glue degrader program targeting CDK2 for broad oncology applications including breast cancer and other solid tumors. Gilead exercised its option in April 2026, triggering a $45 million milestone payment. The agreement includes potential total payments of up to $750 million. Gilead plans to advance KT-200 into IND-enabling studies with an IND submission targeted for 2027, while Kymera retains certain co-development and co-commercialization rights.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2020-07-07
Description

Kymera's partnership with Sanofi is designed to accelerate the path to broader clinical development and commercialization of oral, first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases. Sanofi is progressing the IRAK4 program (KT-485/SAR447971 and first-generation KT-474) through clinical development. Kymera has the option to participate in future development and commercialization, and a 50/50 profit split in the United States, with double-digit tiered royalties in rest of world. The collaboration includes potential for up to $975 million in total development and commercialization milestones. A $20 million milestone was triggered in June 2026 for the Phase 1 trial commencement of KT-485.

Strategic tierMinorTypeOthers
Description

Kymera is engaged with patient advocacy organizations, including the National Eczema Association and International Eczema Council, to better understand unmet needs to inform research and clinical trials.

Strategic tierMinorTypeOthers
Description

Kymera is engaged with patient advocacy organizations including the International Eczema Council to help better understand unmet needs to inform research and clinical trials for atopic dermatitis and related Type 2 inflammatory conditions.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Profitable, multi-product biopharma with similar trajectory from clinical-stage biotech to commercial success in specialty diseases. Relevant benchmark for capital-efficient biopharma scaling.

TypeBroad incumbent
Description

Large-cap biopharma whose Dupixent (dupilumab) is the entrenched injectable biologic KT-621 is positioned to disrupt. Most relevant commercial competitor and benchmark for atopic dermatitis/astha efficacy.

TypeDirect peer
Description

Clinical-stage TPD company developing both catalytic degraders (MonoDACs) and bifunctional degraders (DACOATs). Directly comparable to Kymera with clinical-stage oncology pipeline and similar protein degradation approach.

TypeDirect peer
Description

Clinical-stage company developing molecular glue degraders (MGDs) to treat immunology and oncology indications. Direct competitor in the protein degradation modality with shared mechanism and therapeutic area focus.

TypeDirect peer
Description

Clinical-stage biopharma pioneering targeted protein degradation with PROTAC degraders (ARV-471 in breast cancer, ARV-102 in neurology). Most direct competitor to Kymera in the heterobifunctional degrader space with overlapping modality and clinical-stage assets.

6Bristol Myers Squibb
TypeBroad incumbent
Description

Large-cap biopharma with significant immunology and oncology franchises that overlap with Kymera's target indications. Relevant as a potential strategic acquirer and benchmark for pipeline value in these therapeutic areas.

TypeBroad incumbent
Description

Commercial-stage RNA interference therapeutics company, comparable in modality-pioneering approach (similar to Kymera's TPD modality) with validated pharma partnerships and Kymera board member John Maraganore as former CEO.

TypeDirect peer
Description

Clinical-stage biotech developing targeted protein modulation via degraders (DUBs) and ligases. Directly comparable TPD-focused company with clinical assets in immunology and oncology and major pharma partnerships including Sanofi.

TypeBroad incumbent
Description

Global biopharma with co-marketing rights to Dupixent (through Regeneron partnership) and Kymera's IRAK4 collaborator on KT-485. Comparable as a major immunology player and strategic pharma partner.

TypeEmerging player
Description

Clinical-stage biotech targeting chromatin regulatory dysregulation in cancer through protein degradation-adjacent approaches. Adjacent modality overlap and similar clinical-stage profile.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors25 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kymera Therapeutics

Biopharmaceuticals (Targeted Protein Degradation Therapeutics)kymeratx.com

Kymera Therapeutics is a clinical-stage biopharmaceutical company pioneering targeted protein degradation to develop first-in-class oral small molecule degraders for Type 2 inflammatory, autoimmune, and oncology diseases, serving patients and large pharma partners (Sanofi, Gilead) through wholly owned and partnered programs.

What Kymera Therapeutics does

Kymera Therapeutics is a clinical-stage biopharmaceutical company founded in 2016 that pioneers targeted protein degradation (TPD), a modality which uses heterobifunctional small molecule degraders and molecular glues to redirect the cell's ubiquitin-proteasome system to eliminate disease-causing proteins, including those historically considered undruggable. The company's clinical pipeline is anchored by KT-621, a first-in-class once-daily oral STAT6 degrader in Phase 2b development for moderate-to-severe atopic dermatitis (BROADEN2) and eosinophilic asthma (BREADTH), which received FDA Fast Track designation for both indications based on Phase 1b data showing 98% STAT6 degradation in blood and 94% in skin, with 63% EASI reduction comparable to dupilumab. Additional clinical programs include KT-579 (first-in-class oral IRF5 degrader in Phase 1 for lupus), KT-485 (second-generation IRAK4 degrader in Phase 1, partnered with Sanofi), and KT-200 (first-in-class oral CDK2 molecular glue partnered with Gilead). The pipeline is supported by the proprietary Pegasus discovery platform, which integrates DNA-encoded libraries, fragment-based screening, AI/ML-enabled hit optimization, X-ray crystallography, cryo-EM, and access to over 600 unique E3 ligases to match target proteins with disease-selective ligases.

The Pegasus platform and degrader programs are protected by 500+ issued or pending patents, and the company is led by founder/CEO Nello Mainolfi (former Novartis) with a 250+ employee team headquartered in Watertown, Massachusetts, traded on NASDAQ as KYMR since a 2021 IPO. Kymera generates revenue primarily through collaboration agreements with major pharmaceutical partners — Sanofi (IRAK4 program, up to $975M in milestones plus 50/50 US profit split and double-digit tiered royalties ex-US) and Gilead Sciences (CDK2 program, up to $750M plus royalties, option exercised April 2026) — alongside equity financings; the company has no commercial product revenue, with FY2025 collaboration revenue of $39.2M and Q1 2026 collaboration revenue of $34.36M driven by a Gilead milestone. Management has stated intent to evolve from clinical-stage developer toward a fully integrated biopharma that discovers, develops, and commercializes its own medicines, supported by approximately $1.6B in cash providing runway into 2029 and a market capitalization of approximately $8.2B as of June 2026.

Kymera Therapeutics firmographics

Firmographics
Name
Kymera Therapeutics
Legal name
Kymera Therapeutics, Inc.
Website
https://kymeratx.com
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
251–500 employees
Short description
Kymera Therapeutics is a clinical-stage biopharmaceutical company pioneering targeted protein degradation to develop first-in-class oral small molecule degraders for Type 2 inflammatory, autoimmune, and oncology diseases, serving patients and large pharma partners (Sanofi, Gilead) through wholly owned and partnered programs.
Ownership category
akta.pro rank

Kymera Therapeutics industry classification

Industry
Product category
Biopharmaceuticals (Targeted Protein Degradation Therapeutics)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Targeted protein degradation
  • Protein degrader medicines
  • Small molecule degraders
  • Immunology therapeutics
  • Oncology drug development

Where Kymera Therapeutics is headquartered

Location

Headquarters

HQ city
Watertown
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Kymera Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Collaboration/Partnership Revenue: Kymera generates revenue through strategic collaborations with major pharmaceutical companies. The company has collaboration agreements with Sanofi (IRAK4 program) and Gilead Sciences (CDK2 program), receiving milestone payments and potentially royalties on net sales. As a clinical-stage company with no commercial products, revenue is derived from upfront payments, development and regulatory milestones, and potentially sales milestones and royalties.
  2. Public Offerings / Equity Financing: The company has raised significant capital through public equity offerings. In 2025, the company raised approximately $980.7 million through follow-on public offerings, ending 2025 with $1,619.4 million in cash, cash equivalents, and marketable securities.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Kymera Therapeutics product offering

Product offering

Core offering

Kymera Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops oral small molecule medicines using targeted protein degradation (TPD), a modality that hijacks the cell's natural protein disposal machinery to eliminate disease-causing proteins. Its pipeline includes first-in-class oral degrader candidates (KT-621, KT-579, KT-485, KT-200, KT-474) for immunology and oncology indications, enabled by the proprietary Pegasus drug discovery platform.

Product overview

Kymera Therapeutics is a clinical-stage biopharmaceutical company pioneering targeted protein degradation (TPD) to develop a pipeline of first-in-class oral small molecule degrader medicines. The company's pipeline includes multiple clinical-stage programs: KT-621 (STAT6 degrader) in Phase 2b for atopic dermatitis and asthma; KT-579 (IRF5 degrader) in Phase 1 for lupus; KT-485 (IRAK4 degrader) in Phase 1 partnered with Sanofi; and KT-200 (CDK2 molecular glue degrader) partnered with Gilead. The proprietary Pegasus platform enables the discovery and development of heterobifunctional degraders that engage E3 ligases to selectively eliminate disease-causing proteins, addressing targets previously considered undruggable.

Differentiator

Problem solved

Functional benefit

Products and services

  • KT-621 (STAT6 Degrader) First-in-class, once-daily oral STAT6 degrader for Type 2 inflammatory diseases including moderate-to-severe atopic dermatitis, eosinophilic asthma, COPD, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, prurigo nodularis, and bullous pemphigoid. Demonstrated 98% STAT6 degradation in blood and 94% in skin in Phase 1b, with clinical efficacy comparable to dupilumab.
  • KT-579 (IRF5 Degrader) First-in-class oral IRF5 degrader targeting the historically undrugged transcription factor IRF5 for lupus, Sjögren's syndrome, rheumatoid arthritis, inflammatory bowel disease, systemic sclerosis, and dermatomyositis.
  • KT-485 (IRAK4 Degrader / SAR447971) Second-generation, first-in-class, selective, potent, oral IRAK4 degrader partnered with Sanofi for immune-inflammatory diseases including hidradenitis suppurativa, atopic dermatitis, psoriasis, IBD, asthma, COPD, RA, and SLE.
  • KT-200 (CDK2 Molecular Glue Degrader) First-in-class oral CDK2 molecular glue degrader partnered with Gilead Sciences for breast cancer and other solid tumors. CDK2 is a master regulator of the cell cycle with strong genetic and clinical validation; selectively degrades CDK2 while sparing closely related kinases like CDK1.
  • KT-474 (First-generation IRAK4 Degrader) First-generation oral IRAK4 degrader; the first heterobifunctional small molecule protein degrader outside of oncology to enter clinical development. Completed Phase 1 studies and provided proof-of-concept for the company's degrader modality.
  • Pegasus Discovery Platform Proprietary targeted protein degradation drug discovery platform combining DNA encoded libraries, fragment and X-ray based screenings, machine learning and AI for hit-validation and optimization, structure-based drug design, and global quantitative proteomics to match target proteins with optimal E3 ligases from a library of over 600 unique options.

Quantifiable outcome

  • KT-621 achieved 98% STAT6 degradation in blood and 94% in skin in Phase 1b atopic dermatitis patients
  • +7 more outcomes

Companies that use Kymera Therapeutics

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles1 record

Kymera Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Kymera Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship and minor.

  • Gilead SciencesflagshipStrategic or Co-development Partner · 25 June 2025Kymera and Gilead Sciences entered an exclusive option and license agreement for a novel molecular glue degrader program targeting CDK2 for broad oncology applications including breast cancer and other solid tumors. Gilead exercised its option in April 2026, triggering a $45 million milestone payment. The agreement includes potential total payments of up to $750 million. Gilead plans to advance KT-200 into IND-enabling studies with an IND submission targeted for 2027, while Kymera retains certain co-development and co-commercialization rights.
  • SanofiflagshipStrategic or Co-development Partner · 7 July 2020Kymera's partnership with Sanofi is designed to accelerate the path to broader clinical development and commercialization of oral, first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases. Sanofi is progressing the IRAK4 program (KT-485/SAR447971 and first-generation KT-474) through clinical development. Kymera has the option to participate in future development and commercialization, and a 50/50 profit split in the United States, with double-digit tiered royalties in rest of world. The collaboration includes potential for up to $975 million in total development and commercialization milestones. A $20 million milestone was triggered in June 2026 for the Phase 1 trial commencement of KT-485.
  • National Eczema AssociationminorOthersKymera is engaged with patient advocacy organizations, including the National Eczema Association and International Eczema Council, to better understand unmet needs to inform research and clinical trials.
  • International Eczema CouncilminorOthersKymera is engaged with patient advocacy organizations including the International Eczema Council to help better understand unmet needs to inform research and clinical trials for atopic dermatitis and related Type 2 inflammatory conditions.

Scale indicators9 records

Recent moves6 records

Expansion highlights7 records

Kymera Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Vertex Pharmaceuticals: Profitable, multi-product biopharma with similar trajectory from clinical-stage biotech to commercial success in specialty diseases. Relevant benchmark for capital-efficient biopharma scaling.
  • Regeneron Pharmaceuticals: Large-cap biopharma whose Dupixent (dupilumab) is the entrenched injectable biologic KT-621 is positioned to disrupt. Most relevant commercial competitor and benchmark for atopic dermatitis/astha efficacy.
  • Bristol Myers Squibb: Large-cap biopharma with significant immunology and oncology franchises that overlap with Kymera's target indications. Relevant as a potential strategic acquirer and benchmark for pipeline value in these therapeutic areas.
  • Alnylam Pharmaceuticals: Commercial-stage RNA interference therapeutics company, comparable in modality-pioneering approach (similar to Kymera's TPD modality) with validated pharma partnerships and Kymera board member John Maraganore as former CEO.
  • Sanofi: Global biopharma with co-marketing rights to Dupixent (through Regeneron partnership) and Kymera's IRAK4 collaborator on KT-485. Comparable as a major immunology player and strategic pharma partner.

Direct peers

  • C4 Therapeutics: Clinical-stage TPD company developing both catalytic degraders (MonoDACs) and bifunctional degraders (DACOATs). Directly comparable to Kymera with clinical-stage oncology pipeline and similar protein degradation approach.
  • Monte Rosa Therapeutics: Clinical-stage company developing molecular glue degraders (MGDs) to treat immunology and oncology indications. Direct competitor in the protein degradation modality with shared mechanism and therapeutic area focus.
  • Arvinas: Clinical-stage biopharma pioneering targeted protein degradation with PROTAC degraders (ARV-471 in breast cancer, ARV-102 in neurology). Most direct competitor to Kymera in the heterobifunctional degrader space with overlapping modality and clinical-stage assets.
  • Nurix Therapeutics: Clinical-stage biotech developing targeted protein modulation via degraders (DUBs) and ligases. Directly comparable TPD-focused company with clinical assets in immunology and oncology and major pharma partnerships including Sanofi.

Emerging players

  • Foghorn Therapeutics: Clinical-stage biotech targeting chromatin regulatory dysregulation in cancer through protein degradation-adjacent approaches. Adjacent modality overlap and similar clinical-stage profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Kymera Therapeutics social profiles

Digital presence

Kymera Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kymera Therapeutics leadership team

Management profile

Number of profiles

Profiles18 records

Kymera Therapeutics funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors25 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kymera Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kymera Therapeutics

What does Kymera Therapeutics do?

Kymera Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops oral small molecule medicines using targeted protein degradation (TPD), a modality that hijacks the cell's natural protein disposal machinery to eliminate disease-causing proteins. Its pipeline includes first-in-class oral degrader candidates (KT-621, KT-579, KT-485, KT-200, KT-474) for immunology and oncology indications, enabled by the proprietary Pegasus drug discovery platform.

Is Kymera Therapeutics a public or private company?

Kymera Therapeutics is a public company. It is classified as public and is currently operating.

When was Kymera Therapeutics founded?

Kymera Therapeutics was founded in 2016. It employs 251 to 500 people.

Where is Kymera Therapeutics based?

Kymera Therapeutics is headquartered in Watertown, United States, in the North America region.

How does Kymera Therapeutics make money?

Two revenue lines are on record. Collaboration/Partnership Revenue is the primary driver. The others are public Offerings / Equity Financing.

Who are Kymera Therapeutics's main competitors?

Broad incumbents on record are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Bristol Myers Squibb, Alnylam Pharmaceuticals and Sanofi. Direct peers are C4 Therapeutics, Monte Rosa Therapeutics, Arvinas and Nurix Therapeutics. Foghorn Therapeutics is listed as an emerging player.

Does Kymera Therapeutics have an API?

No public API is recorded for Kymera Therapeutics.

What industry is Kymera Therapeutics in?

Kymera Therapeutics's product category is Biopharmaceuticals (Targeted Protein Degradation Therapeutics). Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver QuantitativeKymera Therapeutics to Report BROADEN2 Phase 2b Results for KT-621 in Atopic Dermatitis on November 23, 2026 | KYMR Stock NewsKymera Therapeutics will announce BROADEN2 Phase 2b trial results for KT-621, an oral STAT6 degrader for atopic dermatitis, on November 23, 2026. The company will hold a video conference call and webcast at 8:00 a.m. ET, with a press release at 7:00 a.m. ET. KT-621 targets Type 2 inflammation diseases, including asthma and COPD.36krClear $10 Billion Market: The Unsolved STAT6 Target and Its Breakthrough Therapeutic PotentialThe clinical development of STAT6 degrader SAR448272 was suspended after only two months in Phase I. Kymera's KT-621 showed a 62.6% EASI score reduction in Phase Ib atopic dermatitis, with Phase IIb data expected by end of 2026. The track faces risks of off-target effects and degradation-efficacy conversion.TradingViewBarclays maintains Kymera Therapeutics at Overweight, raises price target to $170 from $139Barclays maintained Kymera Therapeutics at Overweight and raised its price target to $170 from $139, a 22.3% increase. The target implies a 34.2% upside from the Oct 30 close of $126.63. Recent analyst price targets range from $116 to $150.STATComing readout of Kymera eczema trial is a high-stakes moment in a bid to rival DupixentKymera Therapeutics will announce data from a mid-stage clinical trial of its eczema drug KT-621 before year-end. Analysts call the readout one of the most impactful in immunology this year, with sales forecast near $4 billion by 2035, including over $3 billion in eczema revenue.Defense WorldKymera Therapeutics (NASDAQ:KYMR) Stock Rating Cut to Sell at Wall Street ZenWall Street Zen cut Kymera Therapeutics from a hold to a sell rating. The company reported a Q3 loss of $1.32 per share, missing the $1.26 consensus, and revenue of $1.35 million, below the $3.28 million estimate. Analysts' consensus remains a Moderate Buy with an average target of $137.92.MarketBeatKymera Therapeutics (NASDAQ:KYMR) Stock Rating Lowered by Wall Street ZenWall Street Zen downgraded Kymera Therapeutics from a hold to a sell rating. The company reported Q3 EPS of -$1.32, missing the -$1.26 consensus, and revenue of $1.35 million, below the $3.28 million estimate. Analysts maintain a Moderate Buy consensus with an average target of $137.92.American Banking and Market NewsKymera Therapeutics (NASDAQ:KYMR) Stock Price Expected to Rise, BTIG Research Analyst SaysBTIG Research raised its price target on Kymera Therapeutics to $139 from $134, maintaining a buy rating. The company reported Q3 EPS of -$1.32, missing the -$1.26 consensus, with revenue of $1.35 million below the $3.28 million estimate. Analysts expect a -3.85 EPS for the current year.MarketBeatKymera Therapeutics (NASDAQ:KYMR) Stock Keeps "Buy" Rating at Truist FinancialTruist Financial restated a Buy rating on Kymera Therapeutics with a $150 price target, up from $136. The company reported a Q3 loss of $1.32 per share and revenue of $1.35 million, missing estimates. Analysts have a consensus price target of $137.92.MarketBeatKymera Therapeutics (NASDAQ:KYMR) Stock Price Target Raised at Royal Bank Of CanadaRoyal Bank of Canada raised its price target on Kymera Therapeutics to $116 from $112, citing a sector perform rating. The stock traded down 1.3% to $120.99, and the company reported a Q3 loss of $1.32 per share, missing the $1.26 consensus, with revenue of $1.35 million versus $3.28 million expected.TradingViewRBC Capital maintains Kymera Therapeutics at Sector Perform, raises price target to $116 from $112RBC Capital maintained Kymera Therapeutics at Sector Perform and raised its price target to $116 from $112. The target implies a 5.4% downside from the Oct 29 close of $122.60. Recent analyst price targets range from $139 to $150.